Midodrine Hydrochloride NDC 82293-003

NDC codes

FDA NDC Directory

Product NDC (as listed)82293-003Labeler and product segments. Claims need a package NDC.

Product NDC at billing width82293-0003Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
82293-003-10	82293000310	100 TABLET in 1 BOTTLE (82293-003-10)Marketed from Oct 18, 2023

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Midodrine Hydrochloride
Generic name (nonproprietary): midodrine hydrochloride
Active ingredients: Midodrine hydrochloride — 2.5 mg/1
Dosage form: Tablet
Route: Oral
Labeler: Novugen Pharma (USA) LLC
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 211973
Marketing start: Oct 18, 2023
Listing expires: Dec 31, 2026
Other FDA classes: Adrenergic alpha-Agonists (Mechanism)
Identifiers: Product ID 82293-003_451b5336-7460-7ffc-e063-6294a90aa15bSPL ID 451b5336-7460-7ffc-e063-6294a90aa15bSPL set ID 2bf011fe-d114-42a4-93e2-76a993a3ba34RxCUI 993462, 993466, 993470UNII 59JV96YTXV
Pharmacologic class: alpha-Adrenergic Agonist

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N482293000310 followed by a unit qualifier and the quantity

Package 82293-0003-10. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Dec 4, 2025. This label includes a boxed warning.

Indications (excerpt from the label)

INDICATIONS AND USAGE Midodrine hydrochloride tablets are indicated for the treatment of symptomatic orthostatic hypotension (OH). Because midodrine hydrochloride tablets can cause marked elevation of supine blood pressure (BP > 200 mmHg systolic), it should be used in patients whose lives are considerably impaired despite standard clinical care, including non-pharmacologic treatment (such as support stockings), fluid expansion, and lifestyle alterations. The indication is based on midodrine hydrochloride tablets' effect on increases in 1-minute standing systolic blood pressure, a surrogate marker considered likely to correspond to a clinical benefit. At present, however, clinical benefits o…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 211973

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 211973
Product	Strength	Form · route	Labeler	Product NDC
Midodrine Hydrochloride	Midodrine hydrochloride 5 mg/1	TabletOral	Novugen Pharma (USA) LLC	82293-004
Midodrine Hydrochloride	Midodrine hydrochloride 10 mg/1	TabletOral	Novugen Pharma (USA) LLC	82293-005